PMCB
PharmaCyte Biotech, Inc.Company with tickers: PMCB
CIK
1157075
CUSIP
71715X203
Shares Outstanding
10,735,649
Website
https://ir.pharmacyte.com
13F Activity (30d)
3 filings
2 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $0 | USD | 2026-01-31 | 10-Q | 2026-03-17 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $2,118,102 | USD | 2026-01-31 | 10-Q | 2026-03-17 |
| Research & Development | $93,113 | USD | 2026-01-31 | 10-Q | 2026-03-17 |
| Operating Income | $-2,118,102 | USD | 2026-01-31 | 10-Q | 2026-03-17 |
| Net Income | $746,860 | USD | 2026-01-31 | 10-Q | 2026-03-17 |
| EPS (Basic) | $-0.17 | USD/shares | 2026-01-31 | 10-Q | 2026-03-17 |
| EPS (Diluted) | $-0.17 | USD/shares | 2026-01-31 | 10-Q | 2026-03-17 |